AKTS Aktis Oncology Inc.

NASDAQ
$16.31

Aktis Oncology Inc. (AKTS) is expected to report earnings on February 11, 2027, before the market open. The consensus earnings estimate is a loss of $0.55 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -4.0% since its last earnings release on November 12, 2026.

Aktis Oncology Missed Consensus Estimates
Thursday, November 12, 2026 · 8:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 11
Thursday · Before Open
Earnings Whisper
-
vs ($0.55)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $16.30

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Aktis Oncology Inc.

Akoustis is a high-tech BAW RF filter solutions company that is pioneering next-generation materials science and MEMS wafer manufacturing to address the market requirements for improved RF filters - targeting higher bandwidth, higher operating frequencies and higher output power compared to incumbent polycrystalline BAW technology deployed today.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.